Approvals for relapsed or refractory multiple myeloma, non-radiographic axial spondyloarthritis, and unresectable hepatocellular carcinoma; advisory committee takes vote on potential treatment for anemia of chronic kidney disease; and an oral formulation of pulmonary arterial hypertension treatment.
A bendamustine-based regimen performed similarly to high-dose melphalan in conditioning prior to autologous stem cell transplantation for multiple myeloma.
Researchers sought to determine whether daratumumab maintenance therapy would be effective in patients with newly diagnosed multiple myeloma.
Researchers sought to determine whether a combination therapy with bortezomib-augmented ASCT would have efficacy in patients with ultra high-risk multiple myeloma or plasma cell leukemia.
Researchers sought to determine whether a combination carfilzomib-lenalidomide-dexamethasone induction and consolidation with ASCT would improve survival in patients with MM with cytogenetic abnormalities.
Researchers sought to determine whether carfilzomib-based consolidation and maintenance therapy regimen may yield similar outcomes to those seen with ASCT in patients with MM.
Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
Researchers sought to determine whether BCVA and ocular symptoms could help determine dosing for belantamab mafodotin in patients with r/r multiple myeloma.
Researchers sought to determine whether giving maintenance ixazomib to patients with multiple myeloma who undergo allogeneic hematopoietic stem cell transplantation would have a clinical benefit.
Researchers sought to determine whether the combination of MGTA-145 and plerixafor would be effective for HSC mobilization for autologous transplant in patients with multiple myeloma.
